Skip to content
Find a Provider
Hiroshi Miyamoto, M.D., Ph.D.

Hiroshi Miyamoto, M.D., Ph.D.

UR Medicine Labs

No ratings currently available, see text in Ratings section below for explanation.

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Not Accepting New Patients

Contact

Office (585) 275-3191
Fax (585) 273-3637

About Me

Dr. Miyamoto is a surgical pathologist and the Director of Genitourinary Pathology. He is trained and has worked both as a urologist and as a pathologist. He has also been engaged in research mainly involving bladder and prostate cancers.
Dr. Miyamoto is a surgical pathologist and the Director of Genitourinary Pathology. He is trained and has worked both as a urologist and as a pathologist. He has also been engaged in research mainly involving bladder and prostate cancers.

Languages

English, Japanese

Certified Specialties

Pathology - Anatomic - American Board of Pathology

Faculty Appointments

Professor - Department of Pathology and Laboratory Medicine (SMD)

Professor - Department of Urology (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Fellow, Johns Hopkins University School of Medicine. 2008 - 2009

Residency, Resident, University of Rochester Medical Center. 2005 - 2008

Residency, Resident, Yokohama City University (Japan). 1988 - 1990

Education

MD | Yokohama City University (Japan). 1988

Awards

Ferring Innovation Grants. 2019

Johns Hopkins Greenberg Bladder Cancer Research Award. 2015 - 2016

Department of Defense Prostate Cancer Research Program Idea Development Award. 2013 - 2016

Clinical and Translational Science Institute (CTSI) - Laboratory Support Award (LSA). 2012

Department of Defense Prostate Cancer Research Program Physician Research Training Award. 2009 - 2015

Department of Defense Breast Cancer Research Program Idea Development Award. 2002 - 2005

CaPCURE Award. 1997

Research

Dr. Miyamoto’s primary research interest includes molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signaling in promoting the development and progression of bladder cancer, as well as resistance to non-surgi...
Dr. Miyamoto’s primary research interest includes molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signaling in promoting the development and progression of bladder cancer, as well as resistance to non-surgical therapy. Epidemiological and clinical data indicate that men have a substantially higher risk of bladder cancer, and the underlying mechanisms of how androgens regulate bladder cancer outgrowth will offer explanations for this gender-specific difference. Additionally, as a surgical pathologist, he has been assessing the histopathological and immunohistochemical features of genitourinary cancers primarily to improve their risk stratification.

Publications

Journal Articles

TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens.

Yildiz B, Jean-Gilles J, Giampoli EJ, Kovar-Peltz S, Yang Q, Miyamoto H, Wang Y

American journal of clinical pathology.. 2024 December 5 Epub 12/05/2024.

Cribriform intraductal carcinoma of the prostate may be more aggressive than cribriform conventional/acinar prostatic adenocarcinoma.

Wang Y, Teramoto Y, Miyamoto H

Pathology.. 2024 October 28 Epub 10/28/2024.

A simple risk stratification model for prostate cancer using histopathologic findings of radical prostatectomy.

Semba R, Uchida K, Hirokawa Y, Shiraishi T, Onishi T, Sasaki T, Inoue T, Watanabe M, Miyamoto H

American journal of clinical pathology.. 2024 October 3162 (4):420-425. Epub 1900 01 01.

Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

Nagata Y, Minato A, Aono H, Kimuro R, Higashijima K, Tomisaki I, Harada K, Miyamoto H, Fujimoto N

International journal of molecular sciences.. 2024 September 2625 (19)Epub 09/26/2024.

Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression.

Goto T, Teramoto Y, Nagata Y, Miyamoto H

Discover oncology.. 2024 September 1315 (1):440. Epub 09/13/2024.

Cytologic Assessment of the Supernatants of Formalin Solution Following Histologic Examination of Transurethral Biopsy/Resection Specimens.

Wang Y, Strzepek TJ, Costello DM, Crowley PA, Plavnicky JS, Russell DK, Wu G, Jean-Gilles J, Miyamoto H

Archives of pathology & laboratory medicine.. 2024 September 6 Epub 09/06/2024.

Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression.

Teramoto Y, Elahi Najafi MA, Matsukawa T, Sharma A, Goto T, Miyamoto H

International journal of molecular sciences.. 2024 July 225 (13)Epub 07/02/2024.

Latrophilin-3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis.

Goto T, Yasui M, Teramoto Y, Nagata Y, Mizushima T, Miyamoto H

Molecular carcinogenesis.. 2024 June 24 Epub 06/24/2024.

The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression.

Kashiwagi E, Kawahara T, Kinoshita F, Shiota M, Inokuchi J, Miyamoto H, Eto M

Anticancer research.. 2024 April 44 (4):1369-1376. Epub 1900 01 01.

Clinical significance of location of perineural cancer invasion detected on prostate needle core biopsy.

Gertsen BG, Teramoto Y, Wang Y, Tsuzuki T, Miyamoto H

Virchows Archiv : an international journal of pathology.. 2024 March 15 Epub 03/15/2024.

Prostate Cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-Staging System.

Miyamoto H, Teramoto Y, Numbere N, Wang Y, Joseph JV

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2024 March 37 (3):100429. Epub 01/23/2024.

Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.

Himura R, Kawano S, Nagata Y, Kawai M, Ota A, Kudo Y, Yoshino Y, Fujimoto N, Miyamoto H, Endo S, Ikari A

Chemico-biological interactions.. 2024 January 25388 :110840. Epub 12/18/2023.

Clinical impact of perineural invasion encircled completely vs. incompletely by prostate cancer on needle core biopsy.

Nwanze J, Teramoto Y, Wang Y, Miyamoto H

Human pathology.. 2024 January 143 :71-74. Epub 12/20/2023.

Primary adrenal melanoma: A case report and review of the literature

Cheng GC, Osinski T, Miyamoto H, Frye TP.

Journal of Clinical Urology. 2024; 17(1): 53-56.

Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.

Okuda Y, Kato T, Fujita K, Fushimi H, Miyamoto H, Netto GJ, Nonomura N

Cancer genomics & proteomics.. 2024 21 (2):137-143. Epub 1900 01 01.

Mineralocorticoid receptor signaling inhibits bladder cancer progression.

Nagata Y, Goto T, Teramoto Y, Matsukawa T, Fujimoto N, Miyamoto H

American journal of cancer research.. 2024 14 (2):696-708. Epub 02/15/2024.

Melatonin Inhibits Chemical Carcinogen-mediated Malignant Transformation of Urothelial Cells: Evidence.

Nagata Y, Quynh NT, Aono H, Harada K, Miyamoto H, Fujimoto N

Cancer genomics & proteomics.. 2024 21 (4):388-394. Epub 1900 01 01.

The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.

Fujimoto N, Nagata Y, Shiota M, Minato A, Tomisaki I, Harada K, Miyamoto H

In vivo.. 2024 38 (5):2328-2334. Epub 1900 01 01.

Prognostic significance of the PI-RADS score in men with prostate cancer undergoing radical prostatectomy.

Nwanze J, Teramoto Y, Wang Y, Miyamoto H

American journal of clinical and experimental urology.. 2024 12 (4):162-172. Epub 08/25/2024.

PGC1? as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers.

Teramoto Y, Yang Z, Matsukawa T, Najafi MAE, Goto T, Miyamoto H

American journal of cancer research.. 2024 14 (9):4367-4377. Epub 09/15/2024.

GULP1 as a Downstream Effector of the Estrogen Receptor-? Modulates Cisplatin Sensitivity in Bladder Cancer.

Tatenuma T, Matsukawa T, Goto T, Jiang G, Sharma A, Najafi MAE, Teramoto Y, Miyamoto H

Cancer genomics & proteomics.. 2024 21 (6):557-565. Epub 1900 01 01.

The Clinical Significance of pT3a Lesions as Well as Unilateral Versus Bilateral Invasion Into the Seminal Vesicle in Men With pT3b Prostate Cancer: A Proposal for a New pT3b Subclassification.

Teramoto Y, Numbere N, Wang Y, Miyamoto H

Archives of pathology & laboratory medicine.. 2023 November 1147 (11):1261-1267. Epub 1900 01 01.

Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?

Teramoto Y, Wang Y, Miyamoto H

The Journal of urology.. 2023 October 210 (4):639-648. Epub 07/11/2023.

GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.

Elahi Najafi MA, Yasui M, Teramoto Y, Tatenuma T, Jiang G, Miyamoto H

International journal of molecular sciences.. 2023 September 624 (18)Epub 09/06/2023.

Clinical impact of perineural cancer invasion detected in prostate cores: Involvement of spatially contiguous versus separate biopsy sites.

Teramoto Y, Numbere N, Miyamoto H

Pathology international.. 2023 September 73 (9):473-475. Epub 07/26/2023.

Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.

Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, Tomisaki I, Harada K, Miyamoto H

Anticancer research.. 2023 September 43 (9):3841-3847. Epub 1900 01 01.

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.

Minato A, Kimuro R, Ohno D, Tanigawa K, Kuretake K, Matsukawa T, Takaba T, Jojima K, Harada M, Higashijima K, Nagata Y, Tomisaki I, Harada K, Fujimoto N, Miyamoto H

Anticancer research.. 2023 September 43 (9):4055-4060. Epub 1900 01 01.

The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome.

Lima W, Wang Y, Miyamoto H

Urologic oncology.. 2023 August 41 (8):357.e1-357.e9. Epub 05/02/2023.

Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable.

Wang Y, Teramoto Y, Miyamoto H

Human pathology.. 2023 August 138 :112-120. Epub 06/24/2023.

Deep learning for histopathological segmentation of smooth muscle in the urinary bladder.

Subramanya SK, Li R, Wang Y, Miyamoto H, Cui F

BMC medical informatics and decision making.. 2023 July 1523 (1):122. Epub 07/15/2023.

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.

Khazan N, Quarato ER, Singh NA, Snyder CWA, Moore T, Miller JP, Yasui M, Teramoto Y, Goto T, Reshi S, Hong J, Zhang N, Pandey D, Srivastava P, Morell A, Kawano H, Kawano Y, Conley T, Sahasrabudhe DM, Yano N, Miyamoto H, Aljitawi O, Liesveld J, Becker MW, Calvi LM, Zhovmer AS, Tabdanov ED, Dokholyan NV, Linehan DC, Hansen JN, Gerber SA, Sharon A, Khera MK, Jurutka PW, Rochel N, Kim KK, Rowswell-Turner RB, Singh RK, Moore RG

Cancers.. 2023 June 3015 (13)Epub 06/30/2023.

Recent advances in the understanding of urothelial tumorigenesis.

Yasui M, Cui L, Miyamoto H

Expert review of anticancer therapy.. 2023 May 23 (5):485-493. Epub 04/18/2023.

Clinical Significance of Perineural Invasion by Prostate Cancer Detected on Needle Core Biopsy.

Teramoto Y, Numbere N, Wang Y, Miyamoto H

American journal of clinical pathology.. 2023 February 1159 (2):116-119. Epub 1900 01 01.

The Clinical Impact of Comedonecrosis Within Intraductal Carcinoma of the Prostate.

Wang Y, Teramoto Y, Weisenthal SJ, Goto T, Miyamoto H

Archives of pathology & laboratory medicine.. 2023 January 1147 (1):94-99. Epub 1900 01 01.

Role of androgen receptor signaling in urothelial tumor: Potential application of hormonal therapy to bladder cancer treatment

Miyamoto H.

The Nishinihon Journal of Urology. 2023; 85(4): 170-176.

Protective role of mineralocorticoid receptor signaling in urothelial tumorigenesis.

Nagata Y, Matsukawa T, Goto T, Teramoto Y, Jiang G, Fujimoto N, Miyamoto H

American journal of cancer research.. 2023 13 (2):408-418. Epub 02/15/2023.

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.

Tatenuma T, Miyamoto H

Drug design, development and therapy.. 2023 17 :2325-2333. Epub 08/04/2023.

Malignant solitary fibrous tumor of the urinary bladder progressing to widespread metastases and death: a rare case report and literature review.

Zengin HB, McCabe M, Yildiz B, Sheganoski TJ, Dignan CR, Huber AR, Miyamoto H, Wang Y

International journal of clinical and experimental pathology.. 2023 16 (9):243-251. Epub 09/15/2023.

An Overview of 10 Anniversary of -Advances in Cell Nuclei: Function, Transport and Receptors.

Miyamoto H

Cells.. 2022 December 2312 (1)Epub 12/23/2022.

The Clinical Significance of Either Extraprostatic Extension or Microscopic Bladder Neck Invasion Alone Versus Both in Men With pT3a Prostate Cancer Undergoing Radical Prostatectomy: A Proposal for a New pT3a Subclassification.

Teramoto Y, Numbere N, Wang Y, Miyamoto H

The American journal of surgical pathology.. 2022 December 146 (12):1682-1687. Epub 08/02/2022.

The Clinical Significance of Perineural Invasion by Prostate Cancer on Needle Core Biopsy: Involvement of Single Versus Multiple Sextant Sites.

Bell PD, Teramoto Y, Gurung PMS, Numbere N, Yang Z, Miyamoto H

Archives of pathology & laboratory medicine.. 2022 October 1146 (10):1252-1257. Epub 1900 01 01.

Prostatic malakoplakia: clinicopathological assessment of a multi-institutional series of 49 patients.

Acosta AM, Sangoi AR, Maclean F, Trpkov K, Osunkoya AO, Collins K, Miyamoto H, Hirsch MS, Chan E, Tretiakova M, Mohanty SK, Kaushal S, Cornejo KM, Aron M, Quiroga-Garza G, Arora K, Nguyen JK, Williamson SR, Epstein JI, Matoso A

Histopathology.. 2022 October 81 (4):520-528. Epub 08/07/2022.

Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin: Multi-institutional Evaluation of 85 Cases.

Acosta AM, Gordetsky JB, Collins K, Osunkoya AO, Sangoi AR, Miyamoto H, Kao CS, Trpkov K, Van Leenders GJLH, Wobker SE, Maclean F, Lal P, Daniel RE, Brimo F, Wasco M, Hirsch MS, Baniak N, Diaz-Perez JA, Cornejo KM, Choy B, Mehra R, Williamson SR, Epstein JI, Matoso A

The American journal of surgical pathology.. 2022 September 146 (9):1269-1276. Epub 04/13/2022.

2020 Editor's Choice Articles in the "Cell Nuclei: Function, Transport and Receptors" Section.

Miyamoto H

Cells.. 2022 August 2411 (17)Epub 08/24/2022.

The Clinical Impact of Unilateral Versus Bilateral Invasion Into the Seminal Vesicle in Patients With Prostate Cancer Undergoing Radical Prostatectomy.

Numbere N, Teramoto Y, Gurung PMS, Wang Y, Yang Z, Miyamoto H

Archives of pathology & laboratory medicine.. 2022 July 1146 (7):855-861. Epub 1900 01 01.

The Clinical Impact of pT3a Lesions in Patients With pT3b Prostate Cancer Undergoing Radical Prostatectomy.

Numbere N, Teramoto Y, Gurung PMS, Goto T, Yang Z, Miyamoto H

Archives of pathology & laboratory medicine.. 2022 May 1146 (5):619-625. Epub 1900 01 01.

Pulse granuloma in the distal ureter, a malignancy mimicker.

Findeis SK, Rashid H, Miyamoto H, Hao Y

Pathology international.. 2022 May 72 (5):318-319. Epub 03/10/2022.

Radical prostatectomy findings and oncologic outcomes in patients with prostate cancer detected on systematic sextant biopsy only, MRI-targeted biopsy only, or both.

Suresh N, Teramoto Y, Wang Y, Miyamoto H

Urologic oncology.. 2022 May 40 (5):193.e7-193.e14. Epub 04/08/2022.

Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors .

Khazan N, Kim KK, Hansen JN, Singh NA, Moore T, Snyder CWA, Pandita R, Strawderman M, Fujihara M, Takamura Y, Jian Y, Battaglia N, Yano N, Teramoto Y, Arnold LA, Hopson R, Kishor K, Nayak S, Ojha D, Sharon A, Ashton JM, Wang J, Milano MT, Miyamoto H, Linehan DC, Gerber SA, Kawar N, Singh AP, Tabdanov ED, Dokholyan NV, Kakuta H, Jurutka PW, Schor NF, Rowswell-Turner RB, Singh RK, Moore RG

Journal of medicinal chemistry.. 2022 April 2865 (8):6039-6055. Epub 04/11/2022.

Limited Adenocarcinoma of the Prostate on Needle Core Biopsy.

Bell PD, Teramoto Y, Gurung PMS, Yang Z, Miyamoto H

Archives of pathology & laboratory medicine.. 2022 April 1146 (4):469-477. Epub 1900 01 01.

Clinical significance of perineural invasion by prostate cancer on magnetic resonance imaging-targeted biopsy.

Suresh N, Teramoto Y, Goto T, Wang Y, Miyamoto H

Human pathology.. 2022 March 121 :65-72. Epub 01/19/2022.

Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience.

Rodriguez Pena MDC, Canete-Portillo S, Amin A, Aron M, Colombo P, Cox R, Baydar DE, Gallegos I, Khani F, Michalova K, Lucianò R, Miyamoto H, Osunkoya AO, Raspollini MR, Sánchez DF, Scarfo F, So JS, Zynger DL, Wei S, Netto GJ, Magi-Galluzzi C

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2022 February 35 (2):249-255. Epub 09/09/2021.

Programmed cell death-ligand?1 expression in different molecular subtypes of upper tract urothelial carcinoma.

Tomiyama E, Fujita K, Hashimoto M, Miyamoto H, Netto GJ, Nonomura N

International journal of urology : official journal of the Japanese Urological Association.. 2022 January 29 (1):89-90. Epub 09/13/2021.

Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series.

Cornell C, Khani F, Osunkoya AO, Matoso A, Miyamoto H, Gordetsky JB, Salaria SN, Giannico GA

Human pathology.. 2022 January 119 :69-78. Epub 11/19/2021.

Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer.

Silvers CR, Messing EM, Miyamoto H, Lee YF

British journal of cancer.. 2021 November 125 (10):1399-1407. Epub 09/25/2021.

Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features.

Rizzo NM, Sholl LM, Idrees MT, Cheville JC, Gupta S, Cornejo KM, Miyamoto H, Hirsch MS, Collins K, Acosta AM

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2021 October 34 (10):1935-1946. Epub 06/08/2021.

Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer.

Teramoto Y, Jiang G, Goto T, Mizushima T, Nagata Y, Netto GJ, Miyamoto H

International journal of molecular sciences.. 2021 September 1722 (18)Epub 09/17/2021.

Intraoperative pathology consultation during urological surgery: Impact on final margin status and pitfalls of frozen section diagnosis.

Miyamoto H

Pathology international.. 2021 September 71 (9):567-580. Epub 06/21/2021.

Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.

Ide H, Miyamoto H

Cells.. 2021 May 1110 (5)Epub 05/11/2021.

Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.

Huang SB, Thapa D, Munoz AR, Hussain SS, Yang X, Bedolla RG, Osmulski P, Gaczynska ME, Lai Z, Chiu YC, Wang LJ, Chen Y, Rivas P, Shudde C, Reddick RL, Miyamoto H, Ghosh R, Kumar AP

Cancer letters.. 2021 May 1505 :24-36. Epub 02/19/2021.

Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.

Fi SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, Costello T, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong MX, Kryvenko ON, Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Pavlovich CP, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Epstein JI

Urologic oncology.. 2021 May 39 (5):295.e1-295.e8. Epub 09/15/2020.

The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.

Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong Q, Kryvenko ON, Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Trpkov K

Archives of pathology & laboratory medicine.. 2021 April 1145 (4):461-493. Epub 1900 01 01.

Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer.

Jiang G, Teramoto Y, Goto T, Mizushima T, Inoue S, Ide H, Nagata Y, Kashiwagi E, Baras AS, Netto GJ, Yang Z, Miyamoto H

Cancers.. 2021 February 2613 (5)Epub 02/26/2021.

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer.

Batth IS, Huang SB, Villarreal M, Gong J, Chakravarthy D, Keppler B, Jayamohan S, Osmulski P, Xie J, Rivas P, Bedolla R, Liss MA, Yeh IT, Reddick R, Miyamoto H, Ghosh R, Kumar AP

International journal of molecular sciences.. 2021 February 1222 (4)Epub 02/12/2021.

Editorial comments to the articles published in volume 8

Miyamoto H.

Integrative Cancer Science and Therapeutics. 2021; 8(6): 1000363.

The Role of Estrogen Receptors in Urothelial Cancer.

Goto T, Miyamoto H

Frontiers in endocrinology.. 2021 12 :643870. Epub 03/16/2021.

The impact of routine frozen section analysis during partial cystectomy for bladder cancer on surgical margin status and long-term oncologic outcome.

Sharma M, Nagata Y, Yang Z, Miyamoto H

Urologic oncology.. 2020 December 38 (12):933.e1-933.e6. Epub 05/08/2020.

The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.

Nagata Y, Miyamoto H

Translational cancer research.. 2020 October 9 (10):6596-6608. Epub 1900 01 01.

FOXO1 inactivation induces cisplatin resistance in bladder cancer.

Ide H, Goto T, Teramoto Y, Mizushima T, Jiang G, Nagata Y, Inoue S, Baras AS, Kashiwagi E, Miyamoto H

Cancer science.. 2020 September 111 (9):3397-3400. Epub 07/17/2020.

Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.

Mizushima T, Jiang G, Kawahara T, Li P, Han B, Inoue S, Ide H, Kato I, Jalalizadeh M, Miyagi E, Fukuda M, Reis LO, Miyamoto H

Molecular cancer therapeutics.. 2020 September 19 (9):1930-1942. Epub 07/31/2020.

Impact of Vasectomy on the Development and Progression of Prostate Cancer: Preclinical Evidence.

Kawahara T, Teramoto Y, Li Y, Ishiguro H, Gordetsky J, Yang Z, Miyamoto H

Cancers.. 2020 August 1512 (8)Epub 08/15/2020.

The Role of Steroid Hormone Receptors in Urothelial Tumorigenesis.

Ide H, Miyamoto H

Cancers.. 2020 August 412 (8)Epub 08/04/2020.

Estrogen receptor ? promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways.

He M, Yu W, Chang C, Miyamoto H, Liu X, Jiang K, Yeh S

Molecular oncology.. 2020 August 14 (8):1779-1799. Epub 06/28/2020.

Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches.

Yin PN, Kc K, Wei S, Yu Q, Li R, Haake AR, Miyamoto H, Cui F

BMC medical informatics and decision making.. 2020 July 1720 (1):162. Epub 07/17/2020.

Loss of DNA mismatch repair proteins in prostate cancer.

Sharma M, Yang Z, Miyamoto H

Medicine.. 2020 May 99 (19):e20124. Epub 1900 01 01.

FOXO1 as a tumor suppressor inactivated via AR/ER? signals in urothelial cells.

Ide H, Mizushima T, Jiang G, Goto T, Nagata Y, Teramoto Y, Inoue S, Li Y, Kashiwagi E, Baras AS, Netto GJ, Kawahara T, Miyamoto H

Endocrine-related cancer.. 2020 April 27 (4):231-244. Epub 1900 01 01.

Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?

Goto T, Miyamoto H

Expert review of anticancer therapy.. 2020 April 20 (4):229-231. Epub 03/24/2020.

Cribriform pattern and perineural invasion on MR/US fusion biopsy predict failure of selection criteria for prostatic hemigland ablation.

Mithal P, Truong M, Quarrier S, Lu D, Hollenberg G, Weinberg E, Miyamoto H, Frye T

Urologic oncology.. 2020 February 38 (2):38.e1-38.e8. Epub 11/18/2019.

5?-Reductase inhibitors do not prevent the development and progression of urothelial cancer: In vitro evidence

Nagata Y, Goto T, Jiang G, Teramoto Y, Miyamoto H.

Bladder Cancer. 2020; 6(4): 481-488.

Attenuation of NAD[P]H:quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGF? signaling.

Thapa D, Huang SB, Muñoz AR, Yang X, Bedolla RG, Hung CN, Chen CL, Huang TH, Liss MA, Reddick RL, Miyamoto H, Kumar AP, Ghosh R

Communications biology.. 2020 3 :12. Epub 01/03/2020.

Compound A inhibits urothelial tumorigenesis via both the androgen receptor and glucocorticoid receptor signaling pathways.

Ide H, Inoue S, Mizushima T, Jiang G, Nagata Y, Goto T, Kashiwagi E, Miyamoto H

American journal of translational research.. 2020 12 (5):1779-1788. Epub 05/15/2020.

The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator.

Kashiwagi E, Abe T, Kinoshita F, Ushijima M, Masaoka H, Shiota M, Netto GJ, Eto M, Miyamoto H

American journal of translational research.. 2020 12 (6):3033-3045. Epub 06/15/2020.

Activation of Glucocorticoid Receptor Inhibits the Stem-Like Properties of Bladder Cancer via Inactivating the ?-Catenin Pathway.

Xu C, Sun M, Zhang X, Xu Z, Miyamoto H, Zheng Y

Frontiers in oncology.. 2020 10 :1332. Epub 08/05/2020.

Estrogen receptor-? signaling induces cisplatin resistance in bladder cancer.

Goto T, Kashiwagi E, Jiang G, Nagata Y, Teramoto Y, Baras AS, Yamashita S, Ito A, Arai Y, Miyamoto H

American journal of cancer research.. 2020 10 (8):2523-2534. Epub 08/01/2020.

Effects of ?-adrenergic receptor antagonists on the development and progression of urothelial cancer.

Nagata Y, Kawahara T, Goto T, Inoue S, Teramoto Y, Jiang G, Fujimoto N, Miyamoto H

American journal of cancer research.. 2020 10 (12):4386-4398. Epub 12/01/2020.

Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer.

Ninomiya S, Kawahara T, Tatenuma T, Miyoshi Y, Miyamoto H, Yao M, Uemura H

International journal of urology : official journal of the Japanese Urological Association.. 2019 December 26 (12):1161-1162. Epub 09/18/2019.

Role of glucocorticoid signaling in urothelial tumorigenesis: Inhibition by prednisone presumably through inducing glucocorticoid receptor transrepression.

Ide H, Inoue S, Mizushima T, Kashiwagi T, Zheng Y, Miyamoto H

Molecular carcinogenesis.. 2019 December 58 (12):2297-2305. Epub 09/18/2019.

Conditional reprogramming technology: a new tool for personalized medicine in bladder cancer?

Miyamoto H

Translational cancer research.. 2019 December 8 (Suppl 6):S636-S638. Epub 1900 01 01.

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.

Sharma M, Yang Z, Miyamoto H

Medicine.. 2019 September 98 (38):e17257. Epub 1900 01 01.

The impact of perivesical lymph node metastasis on clinical outcomes of bladder cancer patients undergoing radical cystectomy.

Sharma M, Goto T, Yang Z, Miyamoto H

BMC urology.. 2019 August 1619 (1):77. Epub 08/16/2019.

Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding protein 3 expression.

Yamamoto Y, Fujita K, Munari E, Uemura M, Miyamoto H, Netto GJ

International journal of urology : official journal of the Japanese Urological Association.. 2019 June 26 (6):678-679. Epub 03/10/2019.

Sex Hormone Receptor Signals in Human Malignancies.

Miyamoto H

International journal of molecular sciences.. 2019 May 3120 (11)Epub 05/31/2019.

The Role of Androgen Receptor Signaling in Ovarian Cancer.

Mizushima T, Miyamoto H

Cells.. 2019 February 198 (2)Epub 02/19/2019.

Distribution of androgen receptor expression in the urinary bladder.

Yasui M, Kawahara T, Takamoto D, Izumi K, Uemura H, Miyamoto H

International journal of urology : official journal of the Japanese Urological Association.. 2019 February 26 (2):305-306. Epub 10/31/2018.

Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tract.

Ide H, Jiang G, Mizushima T, Fujita K, Inoue S, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H

Oncology letters.. 2019 January 17 (1):482-487. Epub 09/26/2018.

Expression of PD-L1 and CTLA-4 in female urethral carcinoma.

Ninomiya S, Kawahara T, Mochizuki T, Ishiguro Y, Miyoshi Y, Otani M, Yao M, Miyamoto H, Uemura H

IJU case reports.. 2019 January 2 (1):23-26. Epub 11/23/2018.

Successful treatment with sorafenib for sunitinib-refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib.

Morinaga R, Kawahara T, Teranishi JI, Chuma M, Izumi K, Miyoshi Y, Yao M, Otani M, Miyamoto H, Uemura H

IJU case reports.. 2019 January 2 (1):43-46. Epub 12/28/2018.

The role of mineralocorticoid receptor signaling in genitourinary cancers

Nagata Y, Goto T, Miyamoto H.

Nuclear Receptor Research. 2019; 6: 101410.

Editorial comments to the articles published in issues 1-3 of volume 6

Miyamoto H.

Integrative Cancer Science and Therapeutics. 2019; 6(3): 1000312.

Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.

Miyoshi Y, Ohtaka M, Kawahara T, Ohtake S, Yasui M, Uemura K, Yoneyama S, Yokomizo Y, Uemura H, Miyamoto H, Yao M

Urologia internationalis.. 2019 102 (1):37-42. Epub 10/16/2018.

The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression.

Ide H, Inoue S, Miyamoto H

Cancers.. 2018 December 410 (12)Epub 12/04/2018.

ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling.

Inoue S, Mizushima T, Ide H, Jiang G, Goto T, Nagata Y, Netto GJ, Miyamoto H

Endocrine connections.. 2018 December 17 (12):1397-1408. Epub 1900 01 01.

Prostatic adenocarcinoma with aberrant diffuse expression of high molecular weight cytokeratin.

Sharma M, Miyamoto H

Pathology.. 2018 December 50 (7):787-789. Epub 10/19/2018.

Continuous versus discontinuous tumor involvement: A dilemma in prostate biopsy quantitation.

Bsirini C, Danakas AM, Miyamoto H

The Prostate.. 2018 November 78 (15):1166-1171. Epub 07/11/2018.

Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation.

Hussain SS, Huang SB, Bedolla RG, Rivas P, Basler JW, Swanson GP, Hui-Ming Huang T, Narayanasamy G, Papanikolaou N, Miyamoto H, Yeh IT, Reddick RL, Pollock BH, Ghosh R, Kumar AP

Cancer letters.. 2018 October 1433 :232-241. Epub 07/09/2018.

The Impact of Routine Frozen Section Assessment During Penectomy on Surgical Margin Status and Long-Term Oncologic Outcomes.

Danakas AM, Bsirini C, Miyamoto H

Pathology oncology research : POR.. 2018 October 24 (4):947-950. Epub 06/03/2018.

Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.

Ohtaka M, Kawahara T, Ishiguro Y, Sharma M, Yao M, Miyamoto H, Uemura H

International journal of urology : official journal of the Japanese Urological Association.. 2018 October 25 (10):901-902. Epub 07/24/2018.

Novel 1.3 Mb germline duplication in chromosome 8q21.11 by microarray comparative genomic hybridization plus single nucleotide polymorphism analysis in an adult patient with pancytopenia and urinary bladder complications.

Reyes Barron C, Evans AG, Miyamoto H, Zhang B, Iqbal MA

Clinical case reports.. 2018 October 6 (10):1947-1952. Epub 08/16/2018.

Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.

Ohtake S, Kawahara T, Ishiguro Y, Takeshima T, Kuroda S, Izumi K, Miyamoto H, Uemura H

Molecular and clinical oncology.. 2018 September 9 (3):302-304. Epub 07/03/2018.

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer.

Sharma M, Miyamoto H

Translational andrology and urology.. 2018 September 7 (Suppl 4):S484-S489. Epub 1900 01 01.

Historical and contemporary perspectives on cribriform morphology in prostate cancer.

Truong M, Frye T, Messing E, Miyamoto H

Nature reviews. Urology.. 2018 August 15 (8):475-482. Epub 1900 01 01.

Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.

Ide H, Inoue S, Mizushima T, Jiang G, Chuang KH, Oya M, Miyamoto H

Molecular cancer therapeutics.. 2018 July 17 (7):1566-1574. Epub 05/02/2018.

Nuclear Factor-?B Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.

Inoue S, Ide H, Mizushima T, Jiang G, Netto GJ, Gotoh M, Miyamoto H

Molecular cancer therapeutics.. 2018 June 17 (6):1303-1314. Epub 03/28/2018.

Uridine 5'diphospho-glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract.

Izumi K, Inoue S, Ide H, Fujita K, Mizushima T, Jiang G, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H

International journal of urology : official journal of the Japanese Urological Association.. 2018 May 25 (5):429-435. Epub 02/14/2018.

Role of the androgen receptor in urothelial cancer.

Inoue S, Mizushima T, Miyamoto H

Molecular and cellular endocrinology.. 2018 April 15465 :73-81. Epub 06/23/2017.

Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract.

Inoue S, Ide H, Fujita K, Mizushima T, Jiang G, Kawahara T, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H

International journal of molecular sciences.. 2018 March 819 (3)Epub 03/08/2018.

The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.

Li P, Chen J, Kashiwagi E, Mizushima T, Han B, Inoue S, Ide H, Izumi K, Miyamoto H

British journal of cancer.. 2018 February 6118 (3):416-420. Epub 11/14/2017.

A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens.

Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP

The Journal of urology.. 2018 January 199 (1):106-113. Epub 07/18/2017.

Complete Penile Disassembly for Repair of Epispadias Causes Erectile Tissue Alteration Through Transforming Growth Factor Beta 1 Overexpression in a Rabbit Model.

Tourchi A, Shabaninia M, Stewart M, Miyamoto H, Di Carlo H, Gearhart J

Urology.. 2018 January 111 :151-156. Epub 09/06/2017.

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, Netto GJ, Miyamoto H

British journal of cancer.. 2018 January 118 (2):213-223. Epub 11/09/2017.

Is Tubulocystic Renal Cell Carcinoma Real?: Genomic Analysis Confirms the World Health Organization Classification.

Ding Y, Miyamoto H, Rothberg PG

The Journal of molecular diagnostics : JMD.. 2018 January 20 (1):28-30. Epub 11/16/2017.

DeltaNp63 expression is a biomarker to predict survival after recurrence of upper urinary tract urothelial carcinoma

Hayashi Y, Fujita K, Yoshida T, Kato T, Kawashima A, Ujike T, Nagahara A, Uemura M, Inoue M, Fushimi H, Imamura R, Yamaguchi S, Miyamoto H, Nonomura N.

Integrative Cancer Science and Therapeutics. 2018; 5(1): 100265.

Utility of magnetic resonance imaging in the detection of prostate cancer with targeted biopsy and prediction of tumor aggressiveness

Miyamoto H.

Nephrology & Urology. 2018; 7(3): 269-272.

STAT3 expression is a prognostic marker in upper urinary tract urothelial carcinoma.

Matsuzaki K, Fujita K, Hayashi Y, Matsushita M, Nojima S, Jingushi K, Kato T, Kawashima A, Ujike T, Nagahara A, Uemura M, Imamura R, Yamaguchi S, Fushimi H, Miyamoto H, Morii E, Nonomura N

PloS one.. 2018 13 (8):e0201256. Epub 08/09/2018.

ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor.

Inoue S, Ide H, Mizushima T, Jiang G, Kawahara T, Miyamoto H

American journal of cancer research.. 2018 8 (11):2325-2336. Epub 11/01/2018.

Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer.

Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF

Oncotarget.. 2017 October 318 (53):91199-91208. Epub 08/08/2017.

Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer.

Ohtaka M, Miyoshi Y, Kawahara T, Ohtake S, Yasui M, Uemura K, Yoneyama S, Hattori Y, Teranishi JI, Yokomizo Y, Uemura H, Miyamoto H, Yao M

Urologic oncology.. 2017 October 35 (10):607.e9-607.e14. Epub 06/20/2017.

Thymol inhibits bladder cancer cell proliferation via inducing cell cycle arrest and apoptosis.

Li Y, Wen JM, Du CJ, Hu SM, Chen JX, Zhang SG, Zhang N, Gao F, Li SJ, Mao XW, Miyamoto H, Ding KF

Biochemical and biophysical research communications.. 2017 September 16491 (2):530-536. Epub 04/04/2017.

Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology.

Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP

The Journal of urology.. 2017 August 198 (2):316-321. Epub 02/03/2017.

Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy.

Truong M, Rais-Bahrami S, Nix JW, Messing EM, Miyamoto H, Gordetsky JB

Human pathology.. 2017 August 66 :206-211. Epub 07/11/2017.

NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract.

Kawahara T, Inoue S, Fujita K, Mizushima T, Ide H, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H

Translational oncology.. 2017 June 10 (3):318-323. Epub 03/19/2017.

GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.

Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, Fushimi H, Netto GJ, Nonomura N, Miyamoto H

Human pathology.. 2017 June 64 :83-90. Epub 04/17/2017.

Androgen receptor activation: a prospective therapeutic target for bladder cancer?

Mizushima T, Tirador KA, Miyamoto H

Expert opinion on therapeutic targets.. 2017 March 21 (3):249-257. Epub 01/19/2017.

Androgen Receptor Signaling in Bladder Cancer.

Li P, Chen J, Miyamoto H

Cancers.. 2017 February 229 (2)Epub 02/22/2017.

Clinical benefits of frozen section assessment during urological surgery: Does it contribute to improving surgical margin status and patient outcomes as previously thought?

Miyamoto H

International journal of urology : official journal of the Japanese Urological Association.. 2017 January 24 (1):25-31. Epub 11/08/2016.

ZKSCAN3 expression in urothelial carcinoma of the upper urinary tract and its impact on patient outcomes.

Jalalizadeh M, Inoue S, Fujita K, Ide H, Mizushima T, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H.

Integrative Cancer Science and Therapeutics. 2017; 4(3): 1000241.

The neutrophil-to-lymphocyte ratio is an effective prognostic marker in localized upper urinary tract urothelial carcinoma treated with nephroureterectomy.

Ohtaka M, Kawahara T, Mochizuki T, Ishida H, Kuroda S, Shinbori M, Hattori Y, Teranishi J, Makiyama K, Miyoshi Y, Yumura Y, Miyamoto H, Yao M, Uemura H.

Integrative Cancer Science and Therapeutics. 2017; 4(4): 1000246.

Renal cell carcinoma with osseous metaplasia: A case report and literature review

Maioli H, Sharma M, Crane GM, Wu G, Miyamoto H.

Integrative Cancer Science and Therapeutics. 2017; 4(6): 1000259.

RANK/RANKL expression in prostate cancer.

Ohtaka M, Kawahara T, Mochizuki T, Takamoto D, Hattori Y, Teranishi JI, Miyoshi Y, Yumura Y, Hasumi H, Yokomizo Y, Hayashi N, Kondo K, Yao M, Miyamoto H, Uemura H

International journal of surgery case reports.. 2017 30 :106-107. Epub 11/29/2016.

Renal Papillary and Calyceal Lesions at CT Urography: Genitourinary Imaging.

Kawamoto S, Duggan P, Sheth S, Miyamoto H, Kazi ZN, Fishman EK

Radiographics : a review publication of the Radiological Society of North America, Inc.. 2017 37 (1):358-359. Epub 1900 01 01.

Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.

Ide H, Inoue S, Miyamoto H

PloS one.. 2017 12 (3):e0174746. Epub 03/31/2017.

Lack of an association between the aPKC?/? expression in prostate cancer and the patient outcomes.

Yokomizo Y, Kawahara T, Nagashima Y, Ishiguro H, Kato I, Yao M, Miyamoto H, Uemura H

International journal of surgery case reports.. 2017 37 :180-182. Epub 06/29/2017.

Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.

Kawahara T, Inoue S, Kashiwagi E, Chen J, Ide H, Mizushima T, Li Y, Zheng Y, Miyamoto H

American journal of cancer research.. 2017 7 (10):2041-2050. Epub 10/01/2017.

Developing a preoperative predictive model for ureteral length for ureteral stent insertion.

Kawahara T, Sakamaki K, Ito H, Kuroda S, Terao H, Makiyama K, Uemura H, Yao M, Miyamoto H, Matsuzaki J

BMC urology.. 2016 November 3016 (1):70. Epub 11/30/2016.

Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract.

Kashiwagi E, Fujita K, Yamaguchi S, Fushimi H, Ide H, Inoue S, Mizushima T, Reis LO, Sharma R, Netto GJ, Nonomura N, Miyamoto H

Cancer biology & therapy.. 2016 November 17 (11):1188-1196. Epub 09/16/2016.

Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.

Kawahara T, Ide H, Kashiwagi E, El-Shishtawy KA, Li Y, Reis LO, Zheng Y, Miyamoto H

Urologic oncology.. 2016 October 34 (10):432.e15-23. Epub 06/18/2016.

ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion.

Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, Netto GJ, Ishiguro H, Miyamoto H

Oncotarget.. 2016 August 167 (33):53599-53610. Epub 1900 01 01.

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H

Oncotarget.. 2016 August 27 (31):49169-49179. Epub 1900 01 01.

Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer.

Kasuga J, Kawahara T, Takamoto D, Fukui S, Tokita T, Tadenuma T, Narahara M, Fusayasu S, Terao H, Izumi K, Ito H, Hattori Y, Teranishi JI, Sasaki T, Makiyama K, Miyoshi Y, Yao M, Yumura Y, Miyamoto H, Uemura H

BMC cancer.. 2016 July 716 :396. Epub 07/07/2016.

Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score.

Kawahara T, Fusayasu S, Izumi K, Yokomizo Y, Ito H, Ito Y, Kurita K, Furuya K, Hasumi H, Hayashi N, Myoshi Y, Miyamoto H, Yao M, Uemura H

BMC urology.. 2016 June 1716 (1):32. Epub 06/17/2016.

Predicting the mineral composition of ureteral stone using non-contrast computed tomography.

Kawahara T, Miyamoto H, Ito H, Terao H, Kakizoe M, Kato Y, Ishiguro H, Uemura H, Yao M, Matsuzaki J

Urolithiasis.. 2016 June 44 (3):231-9. Epub 10/01/2015.

Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.

Kawahara T, Aljarah AK, Shareef HK, Inoue S, Ide H, Patterson JD, Kashiwagi E, Han B, Li Y, Zheng Y, Miyamoto H

The Prostate.. 2016 June 76 (8):744-56. Epub 02/11/2016.

Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.

Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF

Oncotarget.. 2016 April 267 (17):23335-45. Epub 1900 01 01.

Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence.

Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, Yao M, Uemura H

Oncotarget.. 2016 March 227 (12):14153-60. Epub 1900 01 01.

Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.

Kawahara T, Furuya K, Nakamura M, Sakamaki K, Osaka K, Ito H, Ito Y, Izumi K, Ohtake S, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Miyamoto H, Yao M, Uemura H

BMC cancer.. 2016 March 516 :185. Epub 03/05/2016.

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.

Izumi K, Mizokami A, Lin HP, Ho HM, Iwamoto H, Maolake A, Natsagdorj A, Kitagawa Y, Kadono Y, Miyamoto H, Huang CK, Namiki M, Lin WJ

Oncotarget.. 2016 February 167 (7):8389-98. Epub 1900 01 01.

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.

Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, Makiyama K, Miyoshi Y, Miyamoto H, Yao M, Uemura H

BMC cancer.. 2016 February 1616 :111. Epub 02/16/2016.

Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis.

Kawahara T, Kashiwagi E, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H

Molecular carcinogenesis.. 2016 February 55 (2):161-9. Epub 01/15/2015.

Intravesical bacillus Calmette-Guérin therapy for bladder cancer: Molecular mechanisms of action

Jalalizadeh M, Smith AK, Miyamoto H.

Clinical Immunology, Endocrine & Metabolic Drugs. 2016; 3(1): 31-38.

The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer.

Maeda Y, Kawahara T, Kumano Y, Ohtaka M, Kondo T, Mochizuki T, Hattori Y, Teranishi J, Miyoshi Y, Yumura Y, Miyamoto H, Yao M, Uemura H

Urologia internationalis.. 2016 96 (1):123-4. Epub 12/16/2015.

Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy.

Maeda Y, Kawahara T, Koizumi M, Ito H, Kumano Y, Ohtaka M, Kondo T, Mochizuki T, Hattori Y, Teranishi J, Yumura Y, Miyoshi Y, Yao M, Miyamoto H, Uemura H

BioMed research international.. 2016 2016 :6197353. Epub 04/20/2016.

Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy.

Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N, Izumi K, Yokomizo Y, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Yao M, Miyamoto H, Uemura H

Oncotarget.. 2015 October 136 (31):32169-76. Epub 1900 01 01.

ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.

Kawahara T, Shareef HK, Aljarah AK, Ide H, Li Y, Kashiwagi E, Netto GJ, Zheng Y, Miyamoto H

Oncotarget.. 2015 October 66 (30):29860-76. Epub 1900 01 01.

Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.

Zheng Y, Ishiguro H, Ide H, Inoue S, Kashiwagi E, Kawahara T, Jalalizadeh M, Reis LO, Miyamoto H

Molecular endocrinology.. 2015 October 29 (10):1486-97. Epub 08/31/2015.

The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.

Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Ishiguro H, Miyamoto H

The Prostate.. 2015 May 75 (6):573-84. Epub 01/28/2015.

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status.

Lin SJ, Lin CY, Yang DR, Izumi K, Yan E, Niu X, Chang HC, Miyamoto H, Wang N, Li G, Chang C

Neoplasia : an international journal for oncology research.. 2015 April 17 (4):339-47. Epub 1900 01 01.

Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.

Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H

Oncotarget.. 2015 January 306 (3):1582-93. Epub 1900 01 01.

Utility of uroplakin II expression as a marker of urothelial carcinoma.

Tian W, Guner G, Miyamoto H, Cimino-Mathews A, Gonzalez-Roibon N, Argani P, Li X, Sharma R, Subhawong AP, Rezaei K, Bivalacqua TJ, Epstein JI, Bishop JA, Netto GJ

Human pathology.. 2015 January 46 (1):58-64. Epub 10/02/2014.

Discolored ureteral stents: findings in urinalysis and urine culture.

Kawahara T, Miyamoto H, Ito H, Terao H, Uemura H, Kubota Y, Matsuzaki J

PloS one.. 2015 10 (4):e0122984. Epub 04/07/2015.

TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells.

Lin SJ, Yang DR, Wang N, Jiang M, Miyamoto H, Li G, Chang C

Oncoscience.. 2015 2 (2):142-50. Epub 02/09/2015.

Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity.

Ishiguro H, Izumi K, Kashiwagi E, Zheng Y, Li Y, Kawahara T, Miyamoto H

American journal of cancer research.. 2015 5 (2):738-47. Epub 01/15/2015.

Fibroblast ER? promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment.

Yeh CR, Hsu I, Song W, Chang H, Miyamoto H, Xiao GQ, Li L, Yeh S

American journal of cancer research.. 2015 5 (3):1146-57. Epub 02/15/2015.

Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H

American journal of cancer research.. 2015 5 (10):2959-68. Epub 09/15/2015.

Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor.

Ide H, Miyamoto H

Disease markers.. 2015 2015 :840640. Epub 12/07/2015.

Androgen deprivation therapy prevents bladder cancer recurrence.

Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H

Oncotarget.. 2014 December 305 (24):12665-74. Epub 1900 01 01.

Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.

Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S

Oncotarget.. 2014 September 155 (17):7917-35. Epub 1900 01 01.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Izumi K, Lin WJ, Miyamoto H, Huang CK, Maolake A, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M

Journal of cancer research and clinical oncology.. 2014 August 140 (8):1413-9. Epub 04/19/2014.

Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity.

Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y, Miyamoto H

Cancer chemotherapy and pharmacology.. 2014 August 74 (2):249-55. Epub 06/01/2014.

Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression.

Ishiguro H, Kawahara T, Zheng Y, Netto GJ, Miyamoto H

American journal of clinical pathology.. 2014 August 142 (2):157-64. Epub 1900 01 01.

Estrogen receptor ? in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3.

Slavin S, Yeh CR, Jun D, Yu S, Miyamoto H, Messing EM, Yeh S

Carcinogenesis.. 2014 June 35 (6):1301-9. Epub 12/28/2013.

TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system.

Lin SJ, Lee SO, Lee YF, Miyamoto H, Yang DR, Li G, Chang C

Carcinogenesis.. 2014 June 35 (6):1399-406. Epub 02/28/2014.

Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen.

Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, Netto GJ, Miyamoto H

Molecular carcinogenesis.. 2014 April 53 (4):314-24. Epub 11/09/2012.

Loss of GATA3 in bladder cancer promotes cell migration and invasion.

Li Y, Ishiguro H, Kawahara T, Kashiwagi E, Izumi K, Miyamoto H

Cancer biology & therapy.. 2014 April 15 (4):428-35. Epub 01/21/2014.

Androgen receptor antagonists in the treatment of prostate cancer

Kawahara T, Miyamoto H.

Clinical Immunology, Endocrine & Metabolic Drugs. 2014; 1(1): 11-19.

GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.

Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H

American journal of cancer research.. 2014 4 (5):461-73. Epub 09/06/2014.

The impact of frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: a clinicopathologic study of 433 cases.

Venigalla S, Wu G, Miyamoto H

Clinical genitourinary cancer.. 2013 December 11 (4):527-36. Epub 07/17/2013.

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P,

The American journal of surgical pathology.. 2013 October 37 (10):1469-89. Epub 1900 01 01.

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.

Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR,

The American journal of surgical pathology.. 2013 October 37 (10):1490-504. Epub 1900 01 01.

Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations.

Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR,

The American journal of surgical pathology.. 2013 October 37 (10):1505-17. Epub 1900 01 01.

Renal tumors: diagnostic and prognostic biomarkers.

Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H,

The American journal of surgical pathology.. 2013 October 37 (10):1518-31. Epub 1900 01 01.

Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.

Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, Lin WJ, Chang C

Cancer research.. 2013 September 1573 (18):5633-46. Epub 07/22/2013.

Role of frozen section analysis of surgical margins during robot-assisted laparoscopic radical prostatectomy: a 2608-case experience.

Kakiuchi Y, Choy B, Gordetsky J, Izumi K, Wu G, Rashid H, Joseph JV, Miyamoto H

Human pathology.. 2013 August 44 (8):1556-62. Epub 04/02/2013.

Ramelteon combined with an ?1-blocker decreases nocturia in men with benign prostatic hyperplasia.

Kawahara T, Morita S, Ito H, Terao H, Sakata R, Ishiguro H, Tanaka K, Miyamoto H, Matsuzaki J, Kubota Y, Uemura H

BMC urology.. 2013 June 1213 :30. Epub 06/12/2013.

Androgen activates ?-catenin signaling in bladder cancer cells.

Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H

Endocrine-related cancer.. 2013 June 20 (3):293-304. Epub 05/20/2013.

Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.

Hsu JW, Hsu IW, Xu D, Miyamoto H, Liang L, Wu XR, Shyr CR, Chang C

The American journal of pathology.. 2013 May 182 (5):1811-20. Epub 03/13/2013.

Higher expression of peroxisome proliferator-activated receptor ? or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion.

Yang DR, Lin SJ, Ding XF, Miyamoto H, Messing E, Li LQ, Wang N, Chang C

Urology.. 2013 May 81 (5):1109.e1-6. Epub 03/19/2013.

Authors' response to Chew and Lange.

Kawahara T, Ito H, Terao H, Miyamoto H, Uemura H, Kubota Y, Matsuzaki J

Journal of endourology. 2013 April 27 (4):507. Epub 03/15/2013.

Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia.

Ishiguro Y, Ishiguro H, Miyamoto H

Oncotarget.. 2013 April 4 (4):550-9. Epub 1900 01 01.

Histopathologic features of atypical glands on prostate biopsy: nucleolar size is a predictor of subsequent detection of prostatic adenocarcinoma.

Venigalla S, Zhao C, Miyamoto H

The Prostate.. 2013 March 73 (4):376-81. Epub 08/27/2012.

Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis.

Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H

Molecular carcinogenesis.. 2013 February 52 (2):94-102. Epub 11/15/2011.

Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals.

Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H

Molecular cancer therapeutics.. 2012 December 11 (12):2621-32. Epub 10/01/2012.

GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.

Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, Gonzalez-Roibon N, Hicks DG, Tacha D, Netto GJ

Human pathology.. 2012 November 43 (11):2033-40. Epub 05/18/2012.

Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.

Izumi K, Li Y, Zheng Y, Gordetsky J, Yao JL, Miyamoto H

Human pathology.. 2012 November 43 (11):1991-2000. Epub 05/21/2012.

Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.

Izumi K, Zheng Y, Li Y, Zaengle J, Miyamoto H

International journal of oncology.. 2012 November 41 (5):1587-92. Epub 08/21/2012.

Chronic inflammation on initial benign prostate biopsy is a negative predictor of subsequent cancer detection.

Zhao C, Venigalla S, Miyamoto H

Pathology international.. 2012 November 62 (11):774-6. Epub 1900 01 01.

Frozen section assessment in testicular and paratesticular lesions suspicious for malignancy: its role in preventing unnecessary orchiectomy.

Subik MK, Gordetsky J, Yao JL, di Sant'agnese PA, Miyamoto H

Human pathology.. 2012 September 43 (9):1514-9. Epub 03/08/2012.

Clinicopathologic features of prostate cancer in patients diagnosed by age 45 who underwent radical prostatectomy.

Choy B, Gordetsky J, Miyamoto H

European urology.. 2012 August 62 (2):354-5. Epub 05/21/2012.

The role of the androgen receptor in the development and progression of bladder cancer.

Li Y, Izumi K, Miyamoto H

Japanese journal of clinical oncology.. 2012 July 42 (7):569-77. Epub 05/15/2012.

Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.

Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S

BJU international.. 2012 June 109 (11):1716-26. Epub 01/05/2012.

The role of periprostatic and periseminal vesicle lymph node metastasis in the staging and prognosis of prostate cancer.

Subik MK, Yao JL, di Sant'agnese PA, Miyamoto H

Histopathology.. 2012 May 60 (6):1009-10. Epub 02/28/2012.

High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.

Chaux A, Karram S, Miller JS, Fajardo DA, Lee TK, Miyamoto H, Netto GJ

Human pathology.. 2012 January 43 (1):115-20. Epub 08/04/2011.

Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma.

Miyamoto H, Zheng Y, Izumi K

Current cancer drug targets.. 2012 January 12 (1):14-22. Epub 1900 01 01.

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C

Neoplasia : an international journal for oncology research.. 2012 January 14 (1):74-83. Epub 1900 01 01.

Mixed epithelial and stromal tumor of the kidney in a 14-year-old boy.

Choy B, Gordetsky J, Varghese M, Lloyd GL, Wu G, Miyamoto H

Urologia internationalis.. 2012 88 (2):247-8. Epub 01/10/2012.

Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.

Lee TK, Chaux A, Karram S, Miyamoto H, Miller JS, Fajardo DA, Epstein JI, Netto GJ

Human pathology.. 2011 November 42 (11):1799-803. Epub 1900 01 01.

Identification of Gleason pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and relation to morphology.

Fajardo DA, Miyamoto H, Miller JS, Lee TK, Epstein JI

The American journal of surgical pathology.. 2011 November 35 (11):1706-11. Epub 1900 01 01.

Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.

Zheng Y, Izumi K, Yao JL, Miyamoto H

Endocrine-related cancer.. 2011 August 18 (4):451-64. Epub 07/04/2011.

Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience.

Gordetsky J, Findeis-Hosey J, Erturk E, Messing EM, Yao JL, Miyamoto H

Canadian Urological Association journal = Journal de l'Association des urologues du Canada.. 2011 August 5 (4):E47-51. Epub 1900 01 01.

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.

Mir C, Shariat SF, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR

BJU international.. 2011 July 108 (1):24-30. Epub 11/10/2010.

Expression of semenogelins I and II and its prognostic significance in human prostate cancer.

Canacci AM, Izumi K, Zheng Y, Gordetsky J, Yao JL, Miyamoto H

The Prostate.. 2011 July 71 (10):1108-14. Epub 12/28/2010.

Eppin expression in prostate cancer.

Izumi K, Zheng Y, Miyamoto H

European urology.. 2011 June 59 (6):1071-2. Epub 1900 01 01.

Transurethral resection specimens of the bladder: outcome of invasive urothelial cancer involving muscle bundles indeterminate between muscularis mucosae and muscularis propria.

Miyamoto H, Epstein JI

Urology.. 2010 September 76 (3):600-2. Epub 04/14/2010.

Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.

Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, Lee TK, Epstein JI, Netto GJ

Archives of pathology & laboratory medicine.. 2010 August 134 (8):1160-3. Epub 1900 01 01.

Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases.

Lee TK, Miyamoto H, Osunkoya AO, Guo CC, Weiss SW, Epstein JI

The American journal of surgical pathology.. 2010 April 34 (4):502-9. Epub 1900 01 01.

Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases.

Miyamoto H, Montgomery EA, Epstein JI

The American journal of surgical pathology.. 2010 April 34 (4):569-74. Epub 1900 01 01.

Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma.

Miyamoto H, Sharma RB, Illei PB, Epstein JI

The American journal of surgical pathology.. 2010 March 34 (3):418-22. Epub 1900 01 01.

Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.

Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI

Pathology international.. 2010 January 60 (1):1-8. Epub 1900 01 01.

A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.

Miyamoto H, Hernandez DJ, Epstein JI

Human pathology.. 2009 December 40 (12):1693-8. Epub 08/14/2009.

Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.

Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI

The Journal of urology.. 2009 November 182 (5):2274-8. Epub 09/16/2009.

Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls.

Tavora F, Fajardo DA, Lee TK, Lotan T, Miller JS, Miyamoto H, Epstein JI

The American journal of surgical pathology.. 2009 October 33 (10):1540-6. Epub 1900 01 01.

Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma.

Ohta S, Uemura H, Matsui Y, Ishiguro H, Fujinami K, Kondo K, Miyamoto H, Yazawa T, Danenberg K, Danenberg PV, Tohnai I, Kubota Y

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.. 2009 January 107 (1):81-91. Epub 1900 01 01.

Pulmonary metastases from uterine neoplasms after long tumour-free interval: four cases and review of the literature.

Miyamoto H, Jones CE, Raymond DP, Wandtke JC, Strang JG, Bourne PA, Bonfiglio TA, Xu H

Pathology.. 2009 41 (3):234-41. Epub 1900 01 01.

Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C

Cancer research.. 2008 September 168 (17):7110-9. Epub 1900 01 01.

Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1.

Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE

BMC urology.. 2008 April 238 :7. Epub 04/23/2008.

Androgen deprivation therapy for prostate cancer.

Singer EA, Golijanin DJ, Miyamoto H, Messing EM

Expert opinion on pharmacotherapy.. 2008 February 9 (2):211-28. Epub 1900 01 01.

Solitary fibrous tumor of the pancreas: a case report.

Miyamoto H, Molena DA, Schoeniger LO, Haodong Xu

International journal of surgical pathology.. 2007 July 15 (3):311-4. Epub 1900 01 01.

Promotion of bladder cancer development and progression by androgen receptor signals.

Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C

Journal of the National Cancer Institute.. 2007 April 499 (7):558-68. Epub 1900 01 01.

Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54.

Yang Z, Chang YJ, Miyamoto H, Yeh S, Yao JL, di Sant'Agnese PA, Tsai MY, Chang C

Endocrinology.. 2007 March 148 (3):1340-9. Epub 11/16/2006.

ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.

Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, Merry DE, Sobue G, Chen LM, Chang SS, Chang C

Nature medicine.. 2007 March 13 (3):348-53. Epub 03/04/2007.

Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth.

Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant'Agnese PA, Chang C

Molecular endocrinology.. 2007 February 21 (2):343-58. Epub 11/02/2006.

Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.

Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T

Cancer investigation.. 2007 February 25 (1):32-7. Epub 1900 01 01.

C19-steroids as androgen receptor modulators: design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists.

Marwah P, Marwah A, Lardy HA, Miyamoto H, Chang C

Bioorganic & medicinal chemistry.. 2006 September 114 (17):5933-47. Epub 06/08/2006.

Identification of steroid derivatives that function as potent antiandrogens.

Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY, Altuwaijri S, Chang C, Lardy H

International journal of cancer.. 2005 December 10117 (5):866-72. Epub 1900 01 01.

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.

Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C

Molecular carcinogenesis.. 2005 September 44 (1):1-10. Epub 1900 01 01.

Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

Miyamoto H, Messing EM, Chang C

Nature clinical practice. Oncology.. 2005 May 2 (5):236-7. Epub 1900 01 01.

Androgen deprivation therapy for prostate cancer: current status and future prospects.

Miyamoto H, Messing EM, Chang C

The Prostate.. 2004 December 161 (4):332-53. Epub 1900 01 01.

Early versus late hormonal therapy for prostate cancer.

Miyamoto H, Messing EM

Current urology reports.. 2004 June 5 (3):188-96. Epub 1900 01 01.

Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications.

Rahman M, Miyamoto H, Chang C

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2004 April 110 (7):2208-19. Epub 1900 01 01.

Molecular basis for the antiandrogen withdrawal syndrome.

Miyamoto H, Rahman MM, Chang C

Journal of cellular biochemistry.. 2004 January 191 (1):3-12. Epub 1900 01 01.

Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.

Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, Kitamura H, Kubota Y

The Prostate.. 2003 September 156 (4):280-6. Epub 1900 01 01.

Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.

Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C

Cancer research.. 2003 August 1563 (16):4888-94. Epub 1900 01 01.

Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells.

Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C

The Journal of biological chemistry.. 2003 May 30278 (22):19619-26. Epub 03/20/2003.

Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells.

Rahman MM, Miyamoto H, Lardy H, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2003 April 29100 (9):5124-9. Epub 04/16/2003.

3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.

Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2003 April 15100 (8):4440-4. Epub 04/02/2003.

A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth.

Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C

The Journal of biological chemistry.. 2002 February 15277 (7):4609-17. Epub 10/22/2001.

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer.

Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, Takebayashi S, Kitamura H, Hosaka M

Urology.. 2000 May 55 (5):679-83. Epub 1900 01 01.

Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells.

Miyamoto H, Chang C

International journal of urology : official journal of the Japanese Urological Association.. 2000 January 7 (1):32-4. Epub 1900 01 01.

DNA polymerase beta gene mutation in human breast cancer.

Miyamoto H, Miyagi Y, Ishikawa T, Ichikawa Y, Hosaka M, Kubota Y

International journal of cancer.. 1999 November 2683 (5):708-9. Epub 1900 01 01.

Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.

Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE, Chang C

Endocrine.. 1999 October 11 (2):195-202. Epub 1900 01 01.

Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.

Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1999 September 2896 (20):11173-7. Epub 1900 01 01.

Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators.

Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK, Chang C

The Keio journal of medicine.. 1999 June 48 (2):87-92. Epub 1900 01 01.

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.

Miyamoto H, Yeh S, Lardy H, Messing E, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 September 1595 (19):11083-8. Epub 1900 01 01.

Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells.

Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C

Biochemical and biophysical research communications.. 1998 July 20248 (2):361-7. Epub 1900 01 01.

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Miyamoto H, Yeh S, Wilding G, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 June 2395 (13):7379-84. Epub 1900 01 01.

From estrogen to androgen receptor: a new pathway for sex hormones in prostate.

Yeh S, Miyamoto H, Shima H, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 May 1295 (10):5527-32. Epub 1900 01 01.

Comparative study on morning and evening regimens of fleroxacin (FLRX) for the treatment of complicated urinary tract infections

Takeda M, Noguchi K, Masuda M, Yao M, Kinoshita Y, Hosaka M, et al., Shiozaki H, Miyamoto H.

Nishinihon Journal of Urology. 1998; 60(10): 733-744.

Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.

Hayashi H, Miyamoto H, Ito T, Kameda Y, Nakamura N, Kubota Y, Kitamura H

The American journal of pathology.. 1997 August 151 (2):461-70. Epub 1900 01 01.

Hydroxyflutamide may not always be a pure antiandrogen.

Yeh S, Miyamoto H, Chang C

Lancet.. 1997 March 22349 (9055):852-3. Epub 1900 01 01.

Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci.

Miyamoto H, Kubota Y, Shuin T, Shiozaki H

Cancer genetics and cytogenetics.. 1996 June 88 (2):181-3. Epub 1900 01 01.

Telomerase activity in human bladder cancer.

Lin Y, Miyamoto H, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y

Clinical cancer research : an official journal of the American Association for Cancer Research.. 1996 June 2 (6):929-32. Epub 1900 01 01.

Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer.

Miyamoto H, Shuin T, Ikeda I, Hosaka M, Kubota Y

The Journal of urology.. 1996 April 155 (4):1444-7. Epub 1900 01 01.

DNA polymerase beta gene mutations in human bladder cancer.

Matsuzaki J, Dobashi Y, Miyamoto H, Ikeda I, Fujinami K, Shuin T, Kubota Y

Molecular carcinogenesis.. 1996 January 15 (1):38-43. Epub 1900 01 01.

Retinoblastoma gene mutations in primary human prostate cancer.

Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T

The Prostate.. 1995 December 27 (6):314-20. Epub 1900 01 01.

The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer.

Kubota Y, Miyamoto H, Noguchi S, Shuin T, Kitamura H, Xu HJ, Hu SX, Benedict WF

The Journal of urology.. 1995 August 154 (2 Pt 1):371-4. Epub 1900 01 01.

Tumor suppressor gene p53 mutations in human prostate cancer.

Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K

The Prostate.. 1995 July 27 (1):18-24. Epub 1900 01 01.

Expression of transforming growth factor-beta 1 in human bladder cancer.

Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M

Cancer.. 1995 May 1575 (10):2565-70. Epub 1900 01 01.

Retinoblastoma gene mutations in primary human bladder cancer.

Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y

British journal of cancer.. 1995 April 71 (4):831-5. Epub 1900 01 01.

Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.

Miyamoto H, Kubota Y, Fujinami K, Dobashi Y, Kondo K, Yao M, Shuin T, Hosaka M

Oncology research.. 1995 7 (7-8):327-30. Epub 1900 01 01.

[Spontaneous rupture of the hydronephrotic renal parenchyma associated with urinoma in a child].

Miyamoto H, Usuda K

Hinyokika kiyo. Acta urologica Japonica.. 1994 May 40 (5):419-21. Epub 1900 01 01.

Retroperitoneal tumor eleven years after initial treatment of testicular cancer.

Miyamoto H, Moriyama M, Fukushima S, Nakamura N, Kameda Y

Urology.. 1994 January 43 (1):116-7. Epub 1900 01 01.

Oncogenes and tumor suppressor genes in human urogenital cancers

Kubota Y, Miyamoto H, Uemura H, Fujinami K, Shuin T.

Japanese Journal of Clinical Urology. 1994; 48(3): 185-194.

Prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer

Kubota Y, Shuin T, Noguchi S, Ishibashi Y, Miyamoto H, Yao M, Hosaka M, Miura T.

Regional Cancer Treatment. 1994; 7: 193-196.

[Experience with extracorporeal shock wave lithotripsy in children].

Fukushima S, Moriyama M, Miyamoto H

Hinyokika kiyo. Acta urologica Japonica.. 1993 June 39 (6):507-9. Epub 1900 01 01.

[Clinical trial of the systemic chemotherapy for advanced prostatic cancer patients].

Moriyama M, Nomura S, Miyamoto H, Fukushima S

Gan to kagaku ryoho. Cancer & chemotherapy.. 1993 May 20 (7):969-71. Epub 1900 01 01.

Clinical observations on bladder cancer - difference in clinical features with age

Noguchi S, Kubota Y, Shuin T, Miyamoto H, et al.

Acta Urologica Japonica. 1993; 39(12): 1131-1138.

Oncogenes and tumor suppressor genes in human bladder cancer

Kubota Y, Miyamoto H, Shuin T, Kitamura H.

Japanese Journal of Urological Surgery. 1993; 6(6): 495-500.

Spontaneous peripelvic extravasation: Report of two cases

Miyamoto H, Moriyama M, Fukushima S.

Japanese Journal of Urological Surgery. 1993; 6(6): 565-569.

Cryptorchism and chromosomal abnormalities (Edwards, Patau, Lowe syndrome)

Usuda K, Miyamoto H, Hasegawa T, Shimura K.

Nippon-rinsho Naibunptsuishokogun. 1993; : 888-891.

Analyses of p53 gene mutations in primary human bladder cancer.

Miyamoto H, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y, Danenberg K, Danenberg PV

Oncology research.. 1993 5 (6-7):245-9. Epub 1900 01 01.

[A clinical study of 115 patients with testicular tumor].

Miyamoto H, Miura T, Noguchi S, Shuin T, Kubota Y, Hosaka M

Hinyokika kiyo. Acta urologica Japonica.. 1992 July 38 (7):797-802. Epub 1900 01 01.

[Clinical studies on tosufloxacin (TFLX) in urology].

Fukushima S, Moriyama M, Miyamoto H, Hosaka M, Kubota Y, Kinoshita Y, Noguchi K, Shuin T, Noguchi S, Yoshimura S

Hinyokika kiyo. Acta urologica Japonica.. 1992 April 38 (4):501-6. Epub 1900 01 01.

Renal oncocytoma with malignant features

Miyamoto H, Moriyama M, Fukushima S.

Japanese Journal of Urological Surgery. 1992; 5(4): 341-343.

Clinical application of tissue adhesive agent (Fibrin glue) in the field of Urology - Studies on testicular hydrocele

Miyamoto H, Moriyama M, Fukushima S.

Japanese Journal of Clinical Urology. 1992; 46(9): 749-751.

Clinical application of tissue adhesive agent (Fibrin glue) in gaping of postoperative wound

Miyamoto H, Sekiguchi Y, Moriyama M, Fukushima S.

Journal of New Remedies & Clinics. 1992; 41(8): 1941-1943.

Clinical studies on Sulbactam/Cefoperazone in Urology

Fukushima S, Moriyama M, Miyamoto H, et al.

The Japanese Journal of Clinical and Experimental Medicine. 1992; 69(11): 3709-3714.

Clinical studies on lomefloxacin (LFLX) for treatment of acute uncomplicated cystitis

Fukushima S, Moriyama M, Miyamoto H, et al.

Nishinihon Journal of Urology. 1992; 54(12): 2295-2301.

Bellini duct carcinoma of the kidney.

Miyamoto H, Kuwamitsu O, Moriyama M, Sakanishi S, Fujii H, Fukushima S, Sano J, Oaki Y

Urologia internationalis.. 1992 48 (4):460-2. Epub 1900 01 01.

A case of renal pelvic cancer with lung metastasis showing complete remission by MEC (Methotrexate, Etoposide, Cisplatin) therapy

Miyamoto H, Moriyama M, Fukushima S.

The Clinical Report. 1991; 25(5): 1961-1963.

Oncogenes and urogenital cancers

Kubota Y, Shuin T, Misaki H, Yao M, Miyamoto H, Uemura H.

KARKINOS. 1991; 4(3): 289-299.

An effective case of combination therapy with interferon alpha and gamma in advanced renal cell carcinoma

Miyamoto H, Moriyama M, Fukushima S.

Biotherapy. 1991; 5(11): 1827-1829.

[An effective case of M-VAC therapy of advanced bladder cancer with extramammary Paget's disease].

Miyamoto H, Iizawa H, Takahashi T, Miura T, Kinoshita Y, Kubota Y, Hosaka M

Hinyokika kiyo. Acta urologica Japonica.. 1990 December 36 (12):1459-62. Epub 1900 01 01.

Books

Tumor Pathology Differential Diagnosis Atlas: Renal Pelvis, Ureter, and Bladder Cancers (2023)

Chapter: Evaluation of surgical margins during intraoperative frozen section diagnosis

Authors: Miyamoto H

Publisher: Bunkodo 2023

Tumor Pathology Differential Diagnosis Atlas: Renal Pelvis, Ureter, and Bladder Cancers (2023)

Chapter: Hereditary Tumor

Authors: Miyamoto H

Publisher: 2023 2023

Diagnostic Pathology Practice as Guidelines for Cancer Treatment: The Kidney, Urinary Tract, and Male Genitalia (2016)

Chapter: Histological variants of urothelial carcinoma

Authors: Miyamoto H

Publisher: Nakayama Shoten 2016

Genitourinary Pathology: Practical Advances (2015)

Chapter: Intraoperative consultation for prostate tumors: Challenges and implications for treatment

Authors: Miyamoto H, Shen SS

Publisher: Springer, New York 2015

Genitourinary Pathology: Practical Advances (2015)

Chapter: Intraoperative consultation for bladder tumors: Challenges and implications for treatment

Authors: Miyamoto H, Shen SS

Publisher: Springer, New York 2015

Genitourinary Pathology: Practical Advances (2015)

Chapter: Intraoperative consultation for renal tumors: Challenges and implications for treatment

Authors: Miyamoto H, Shen SS

Publisher: Springer, New York 2015

Genitourinary Pathology: Practical Advances (2015)

Chapter: Intraoperative consultation for testicular tumors: Challenges and implications for treatment

Authors: Miyamoto H, Shen SS

Publisher: Springer, New York 2015

Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects (2013)

Chapter: Anti-tumor activities of dexamethasone

Authors: Ishiguro H, Kawahara T, Li Y, Miyamoto H

Publisher: Nova Science Publishers, Hauppauge, New York 2013

Ureters: Anatomy, Physiology and Disorders (2013)

Chapter: Endoscopic management of urolithiasis

Authors: Kawahara T, Ito H, Miyamoto H, Uemura H, Kubota Y, Matsuzaki J

Publisher: Nova Science Publishers, Hauppauge, New York 2013

Koss's Cytology of the Urinary Tract with Histopathologic Correlations (2012)

Chapter: Urine-based assays complementing cytologic examination in the detection of urothelial neoplasm

Authors: Miyamoto H

Publisher: Springer, New York 2012

Atlas Series of Differential Diagnosis of Tumor Histopathology: Renal Pelvis/Ureter/ Bladder Cancer (2012)

Chapter: Differentiation between muscularis mucosae and muscularis propria

Authors: Miyamoto H

Publisher: Bunkodo, Tokyo 2012

Androgen Action in Prostate Cancer (2009)

Chapter: Differential roles of androgen receptor in prostate development and cancer progression

Authors: Yeh S, Niu Y, Miyamoto H, Chang T, Chang C

Publisher: Springer, New York 2009

Current Clinical Oncology: Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies (2008)

Chapter: Androgen receptor in prostate cancer progression

Authors: Miyamoto H, Altuwaijri S, Chang C

Publisher: Humana Press, Totowa, New Jersey 2008

Prostate Cancer – Basic Mechanisms and Therapeutic Approaches (2005)

Chapter: Hormonal therapy for prostate cancer: Clinical and experimental evidence

Authors: Miyamoto H

Publisher: World Scientific, Hackensack, New Jersey 2005

Steroid Hormones and Cell Cycle Regulation (2002)

Chapter: Interaction of cell cycle regulatory proteins with the androgen receptor

Authors: Sampson ER, Yeh S, Miyamoto H, Lee DK, Tsai MY, Wang X, Hsu CL, Chang C

Publisher: Kluwer Academic Publishers, Norwell, Massachusetts 2002

Molecular Basis of Sex Hormone Receptor Function – New Targets for Intervention (1998)

Chapter: The androgen receptor co-regulator, ARA70

Authors: Miyamoto H, Yeh S, Hwang SB, Fujimoto N, Hsiao P, Ting H, Nishimura K, Wang C, Inui S, Uemura H, Kang H, Chang C

Publisher: Springer, Berlin 1998

Proceedings of National Conference of the Japan Society of Andrology (1997)

Chapter: Androgen receptor and androgen receptor cofactors in prostate

Authors: Miyamoto H, Yeh S, Kinoshita H, Fujimoto N, Nishimura K, Inui S, Mizokami A, Uemura H, Chang C

Publisher: Blackwell Publishing 1997

Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH (1994)

Chapter: Analysis of tumor suppressor genes in human prostate cancer by RNA-SSCP method

Authors: Kubota Y, Fujinami K, Uemura H, Miyamoto H, Dobashi Y, Shuin T, Hosaka M, Iwasaki Y, Kitamura H

Publisher: Adenine Press, Tokyo 1994

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.